IL156777A0 - Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists - Google Patents

Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Info

Publication number
IL156777A0
IL156777A0 IL15677702A IL15677702A IL156777A0 IL 156777 A0 IL156777 A0 IL 156777A0 IL 15677702 A IL15677702 A IL 15677702A IL 15677702 A IL15677702 A IL 15677702A IL 156777 A0 IL156777 A0 IL 156777A0
Authority
IL
Israel
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
IL15677702A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of IL156777A0 publication Critical patent/IL156777A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL15677702A 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists IL156777A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
IL156777A0 true IL156777A0 (en) 2004-02-08

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15677702A IL156777A0 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Country Status (28)

Country Link
US (1) US7288517B2 (xx)
EP (1) EP1392348B1 (xx)
JP (1) JP2004529207A (xx)
KR (1) KR20040000446A (xx)
CN (1) CN1317030C (xx)
AT (1) ATE400287T1 (xx)
AU (1) AU2002310788B2 (xx)
BG (1) BG108339A (xx)
BR (1) BR0209290A (xx)
CA (1) CA2444876A1 (xx)
CZ (1) CZ20033167A3 (xx)
DE (1) DE60227507D1 (xx)
DK (1) DK1392348T3 (xx)
ES (1) ES2307760T3 (xx)
HK (1) HK1072000A1 (xx)
HU (1) HUP0400067A2 (xx)
IL (1) IL156777A0 (xx)
MX (1) MXPA03008666A (xx)
NO (1) NO20034322D0 (xx)
NZ (1) NZ544417A (xx)
PL (1) PL362319A1 (xx)
PT (1) PT1392348E (xx)
RU (1) RU2319501C2 (xx)
SI (1) SI1392348T1 (xx)
SK (1) SK14512003A3 (xx)
UA (1) UA80679C2 (xx)
WO (1) WO2002102401A1 (xx)
ZA (1) ZA200305326B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2001271022B2 (en) * 2000-07-05 2006-08-17 Astellas Pharma Inc. Propane-1,3-dione derivatives
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
EP1752452A4 (en) * 2004-06-04 2010-07-14 Astellas Pharma Inc DERIVATIVE OF PROPANE-1, 3-DIONE OR ITS SALT
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
KR101046039B1 (ko) 2005-03-31 2011-07-01 아스텔라스세이야쿠 가부시키가이샤 프로판-1,3-디온 유도체 또는 그의 염
EP2091943B1 (en) 2006-10-21 2013-11-20 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
JP5385282B2 (ja) * 2007-09-11 2014-01-08 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としての血小板フィブリノーゲン受容体ヘキサペプチドアンタゴニストおよびα−エンドルフィンの使用
CA2698768A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
WO1997044339A1 (en) * 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
AU767440B2 (en) 1999-05-14 2003-11-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo(1,2-A)pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
KR20020045609A (ko) 1999-10-15 2002-06-19 추후기재 고나도트로핀-분비 호르몬 수용체 길항제 및 이와 관련된방법
EP1393747A4 (en) 2000-04-13 2004-03-03 Takeda Chemical Industries Ltd AGENT FOR PREVENTION / TREATMENT OF ALZHEIMER DISEASE
AU2001271022B2 (en) 2000-07-05 2006-08-17 Astellas Pharma Inc. Propane-1,3-dione derivatives

Also Published As

Publication number Publication date
SK14512003A3 (sk) 2004-08-03
MXPA03008666A (es) 2004-10-15
AU2002310788B2 (en) 2007-04-05
EP1392348B1 (en) 2008-07-09
DE60227507D1 (de) 2008-08-21
RU2003134949A (ru) 2005-02-10
US7288517B2 (en) 2007-10-30
PT1392348E (pt) 2008-09-09
UA80679C2 (en) 2007-10-25
ATE400287T1 (de) 2008-07-15
CA2444876A1 (en) 2002-12-27
NZ544417A (en) 2008-03-28
HK1072000A1 (en) 2005-08-12
HUP0400067A2 (hu) 2004-04-28
EP1392348A1 (en) 2004-03-03
ZA200305326B (en) 2003-07-30
DK1392348T3 (da) 2008-09-29
BR0209290A (pt) 2004-07-13
CN1317030C (zh) 2007-05-23
NO20034322L (no) 2003-09-26
RU2319501C2 (ru) 2008-03-20
BG108339A (bg) 2004-11-30
CZ20033167A3 (cs) 2004-08-18
US20020177556A1 (en) 2002-11-28
JP2004529207A (ja) 2004-09-24
PL362319A1 (en) 2004-10-18
NO20034322D0 (no) 2003-09-26
SI1392348T1 (sl) 2008-12-31
CN1575185A (zh) 2005-02-02
ES2307760T3 (es) 2008-12-01
WO2002102401A1 (en) 2002-12-27
KR20040000446A (ko) 2004-01-03

Similar Documents

Publication Publication Date Title
HK1072000A1 (en) Treatment of alzheimer's diseases with intemediatedoses of lhrh antagonists
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
MY134906A (en) Prevention and treatment of amyloidogenic disease
MY136707A (en) Thrombopoietin mimetics
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
GB0223040D0 (en) Therapeutic compounds
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
NO20004432L (no) Glysintransportinhibitorer
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
MY124786A (en) Bis-arylsulfones
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2003053136A3 (en) Triple transgenic mouse model of alzheimer's disease
BG105651A (en) Vitronectin receptor antagonist
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
WO2002062383A3 (en) Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000870A (es) Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
AU2002319451A1 (en) Therapeutic strategies for prevention and treatment of alzheimer's disease
YU9099A (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease